Oleolive Inc was awarded Phase 2 STTR funding from the National Institute on Aging to study a novel drug to treat Alzheimer’s Disease
Oleolive Inc was awarded Phase 2 STTR funding from the National Institute on Aging to study a novel drug to treat Alzheimer’s Disease
Oleolive Inc was awarded funding from the National Cancer Institute to study a drug to treat brain cancer.
Oleolive Inc was awarded funding from the National Cancer Institute to study a drug to treat brain cancer.
OLIGEN approved by INCI as first Trade Name for Oleocanthal
OLIGEN approved by INCI as first Trade Name for Oleocanthal
Oleolive Inc was awarded funding from the Department of Defense to develop freeze dried platelets for reducing blood loss in wounded special operations warfighters.
Oleolive Inc was awarded funding from the Department of Defense to develop freeze dried platelets for reducing blood loss in wounded special operations warfighters.
Oleolive Wins Pivotal Small Business Research award for Oleocanthal in Triple Negative Breast Cancer
Oleolive Wins Pivotal Small Business Research award for Oleocanthal in Triple Negative Breast Cancer
Oleolive Inc was awarded funding from the National Heart, Lung, and Blood Institute to study a repurposed drug to treat lung fibrosis.
Oleolive Inc was awarded funding from the National Heart, Lung, and Blood Institute to study a repurposed drug to treat lung fibrosis.
Oleolive awarded NIH funding to study oleocanthal and alzheimer’s
Oleolive awarded NIH funding to study oleocanthal and alzheimer’s